Imagenomix delivers rapid and affordable cancer diagnostic results through advanced AI capabilities so patients receive effective, targeted treatments for their specific cancer type.

Cytospire is developing next generation γδ T cell engagers into impactful cancer therapies.

Pioneering a new category of biotechnology to treat and prevent disease.

Eridu is the pioneer advancing the frontier in AI networking with a solution built from the ground up to deliver the bandwidth, performance and reliability at scale needed by AI data
centers.

Proxima is pioneering the next generation of AI-driven drug discovery for proximity-based therapeutics.

Exciva is developing a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia.

We have discovered a vast, expanded universe of novel proteins encoded by the human genome. In analyzing these proteins, we elucidate their respective biological functions, refining our understanding of the molecular underpinnings of human biology and disease. Armed with this knowledge, we’re aiming to create breakthrough medicines for a multitude of diseases.

Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases.

Brainomix has revolutionized medical imaging with an AI-powered platform that automates validated imaging biomarkers—improving both diagnosis and treatment decisions.

Early brings early disease detection to the comfort of our homes with devices that are accurate, easy to use and beautiful. This allows prompt medical treatment and radically improves chances of survival.

Building the world’s first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences.

Ignota Labs applies deep learning to bioinformatics and cheminformatics datasets to solve drug safety issues, rescuing promising but failing drugs and bringing new life to abandoned projects and new hope to patients.

Glyphic Bio is redefining proteomics with next-generation protein sequencing. While DNA provides the blueprint, proteins determine what actually happens in the body. Glyphic Biotechnologies is developing a first-of-its-kind platform to give researchers unprecedented insights into biology and disease, pushing the boundaries of what’s possible in protein analysis.

Case 45 is building the most advanced precision AI model for oncology, rooted in cancer evolutionary biology. They are targeting healthcare (oncology prognostic and predictive tests in unmet need), and pharma (drug development) business models.

Tandem’s combination of in-person clinic and online care is a unique way to maintain an ongoing relationship with us and pet health and creates the best opportunity for pets to thrive.

Outpace Bio is revolutionizing cell therapy with protein design to cure solid tumors.

Evity is building a new foundation for healthspan—an evidence-based longevity intelligence platform for healthcare systems to help people live longer, healthier lives.

Techion develops hardware and software to provide digital diagnostics for animals, people and our environment

March Biosciences is developing advanced cell therapies, targeting complex diseases like cancer and genetic disorders through precision medicine approaches. Their lead asset, MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells.